Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reversibility of vigabratin-induced visual-field defect.

Literature DB >> 10465180

Reversibility of vigabratin-induced visual-field defect.

Abstract

We report a girl with epilepsy aged 10 years receiving vigabatrin and complaining of bumping into objects and presenting visual-field constriction, which disappeared after vigabatrin withdrawal.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1999 PMID： 10465180 DOI： 10.1016/s0140-6736(99)02095-4

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

15 in total

1. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

Authors: P Hardus; W M Verduin; G Postma; J S Stilma; T T Berendschot; C W van Veelen
Journal: Br J Ophthalmol Date: 2000-07 Impact factor: 4.638

2. Vigabatrin and retinal changes.

Authors: Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal: Doc Ophthalmol Date: 2002-03 Impact factor: 2.379

3. Tangent screens are still useful in the assessment of vigabatrin induced visual field defects.

Authors: J A Olson; A T Purdie; R J Coleman
Journal: Br J Ophthalmol Date: 2002-08 Impact factor: 4.638

4. Gabapentin may cause reversible visual field constriction: learning or inattention artefact a more likely explanation.

Authors: Tom Eke
Journal: BMJ Date: 2006-06-24

Reversibility of vigabratin-induced visual-field defect.

1. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

2. Vigabatrin and retinal changes.

3. Tangent screens are still useful in the assessment of vigabatrin induced visual field defects.

4. Gabapentin may cause reversible visual field constriction: learning or inattention artefact a more likely explanation.

Review 5. A risk-benefit assessment of treatments for infantile spasms.

6. Visual field constriction and electrophysiological changes associated with vigabatrin.

Review 7. Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Review 8. Adverse reactions to new anticonvulsant drugs.

9. Visual field defects in pediatric patients on vigabatrin monotherapy.

10. Vigabatrin and visual field defects in pediatric epilepsy patients.